Shandong Jincheng Pharmaceutical Group Co., Ltd

Equities

300233

CNE100001500

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-05-16 EDT 5-day change 1st Jan Change
17.49 CNY -0.06% Intraday chart for Shandong Jincheng Pharmaceutical Group Co., Ltd -4.27% +4.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chinese Drug Regulator Gives Thumbs Up to Jincheng Pharmaceutical Unit's Application to Raise Cefadroxil Dry Suspension's Dosage MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on February 2, 2024. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback announced on February 2, 2024, has closed with 4,543,000 shares, representing 1.18% for CNY 55 million. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 70 million worth of its shares. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd authorizes a Buyback Plan. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jincheng Pharmaceutical Gets License to Produce E-Cigarette Nicotine MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Directorate Appointments CI
Three Jincheng Pharmaceutical Medicines Shortlisted For China’s Drug Procurement Program MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Jincheng Pharma Secures China's First License to Produce E-Cigarettes; Shares Slide 5% MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Shandong Jincheng Pharmaceutical : Pharma Buys Back More Shares; Shares Slide Nearly 3% MT
Tranche Update on Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on April 29, 2021. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback announced on April 29, 2021, has closed with 3,536,400 shares, representing 0.9% for CNY 80 million. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 80 million worth of its shares. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Chart Shandong Jincheng Pharmaceutical Group Co., Ltd
More charts
Shandong Jincheng Pharmaceutical Group Co Ltd, formerly Shandong Jincheng Pharmaceutical Co Ltd, is a China-based company mainly engaged in pharmaceutical manufacturing. The Company operates primarily through three segments. Intermediates segment mainly produces cephalosporin side chain pharmaceutical intermediates and other pharmaceutical and chemical products. Preparation segment focuses on the antimicrobial field and women's health technology. Specialty Active Pharmaceutical Ingredients segment includes biological specialty active pharmaceutical ingredients and chemical active pharmaceutical ingredients. The Company also operates other businesses.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300233 Stock
  4. News Shandong Jincheng Pharmaceutical Group Co., Ltd
  5. Shandong Jincheng Pharma Maintains Final Dividend After Swinging to Profit in 2021
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW